The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 03, 2017

Filed:

Feb. 02, 2015
Applicant:

Immungene Inc., Camarillo, CA (US);

Inventors:

Iqbal Grewal, Chalfont, PA (US);

Sanjay Khare, Palo Alto, CA (US);

Michael Gresser, Ojai, CA (US);

Rashid Syed, Thousand Oaks, CA (US);

Assignee:

IMMUNGENE INC, Camarillo, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/21 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C07K 14/56 (2006.01); C07K 16/30 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2887 (2013.01); A61K 38/212 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 14/56 (2013.01); C07K 16/18 (2013.01); C07K 16/2803 (2013.01); C07K 16/2827 (2013.01); C07K 16/2851 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); C07K 2317/73 (2013.01); C07K 2317/90 (2013.01); C07K 2319/00 (2013.01); C07K 2319/33 (2013.01);
Abstract

The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-α) mutant molecule. The engineered Ab-IFN-α mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-α fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-α fusion molecules.


Find Patent Forward Citations

Loading…